Summary
12X1 Chart
Does Anavex's Alzheimer's Drug Actually Confer Benefit?
Anavex Life Sciences' OLE study demonstrates that its Alzheimer's drug works for years beyond the clinical study. The OLE expands efficacy to include patients' behavioral abilities. The Anavex drug may offer years of extra mental lucidity and greater self-sufficiency among Alzheimer's patients. The EU's approval of Blarcamesine could increase Anavex's market value from $800 million to $8 billion.
The Unusual Effects Of Anavex's Blarcamesine On Alzheimer's Disease (Upgrade)
Blarcamesine shows limited effectiveness against mild Alzheimer's disease, but not against moderate Alzheimer's. However, it does appear effective when started early. These result could lead to European Medicines Agency approval. The benefits of blarcamesine may increase over time due to reduced oxidative stress, though side effects like diziness and confusion may occur. Given the lack of effective Alzheimer's treatments, I cautiously recommend buying Anavex stock based on these promising results.
Anavex Life Sciences to Participate at Upcoming Healthcare Conferences
H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ and H.C. Wainwright 6th Annual Neuro Perspectives Conference
Anavex Life Sciences Corp. Dividends
Anavex Life Sciences Corp. Earnings
| 4 Aug 2025 (62 Days) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 25 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
| 4 Aug 2025 (62 Days) Date | | - Cons. EPS | - EPS |
| 7 May 2025 Date | | - Cons. EPS | - EPS |
| 5 Feb 2025 Date | | - Cons. EPS | - EPS |
| 25 Nov 2024 Date | | - Cons. EPS | - EPS |
| 6 Aug 2024 Date | | - Cons. EPS | - EPS |
Anavex Life Sciences Corp. (12X1) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Anavex Life Sciences Corp. ever had a stock split?
Anavex Life Sciences Corp. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Christopher U. Missling M.B.A., M.S., Ph.D. CEO | XSTU Exchange | US0327973006 ISIN |
| US Country | 42 Employees | - Last Dividend | 7 Oct 2015 Last Split | 2 Aug 2006 IPO Date |
Overview
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases affecting the central nervous system (CNS). With a strategic approach to leveraging its proprietary compounds, the company is at the forefront of addressing significant needs in the healthcare sector, particularly for conditions with limited or no effective treatments. Since its inception in 2004, Anavex has committed to exploring the potential of its drug candidates in treating a variety of CNS diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, and a spectrum of rare neurological disorders. Headquartered in New York, New York, Anavex is dedicated to advancing its clinical programs to bring innovative solutions to patients worldwide.
Products and Services
- ANAVEX 2-73
As the lead product candidate, ANAVEX 2-73 is currently under development for the treatment of Alzheimer's disease and Parkinson's disease. The therapeutic potential of ANAVEX 2-73 also extends to other central nervous system diseases, including rare diseases such as Rett syndrome - a severe neurological disorder, infantile spasms, Fragile X syndrome, and Angelman syndrome. ANAVEX 2-73's versatility demonstrates Anavex's commitment to addressing a broad range of neurological conditions.
- ANAVEX 3-71
Further in the pipeline, ANAVEX 3-71 is under clinical trials targeting the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. This drug candidate emphasizes Anavex's targeted therapeutic approach to CNS diseases, showcasing the company's innovative research in developing treatments for mental health conditions and neurodegenerative disorders.
- Preclinical Drug Candidates
- ANAVEX 1-41
Designed for the treatment of depression, stroke, and neurodegenerative diseases, ANAVEX 1-41 is at the preclinical stage, exploring its potential to address a wide array of CNS conditions. Its development underlines Anavex's commitment to expanding its treatment landscape to include mental health disorders and the consequences of cerebrovascular accidents.
- ANAVEX 1066
ANAVEX 1066 is being investigated for its potential in treating neuropathic and visceral pain. This candidate highlights Anavex's venture into pain management, an area of significant unmet medical need, particularly for patients suffering from chronic conditions.
- ANAVEX 1037
Targeting the treatment of prostate and pancreatic cancer, ANAVEX 1037 showcases Anavex Life Sciences Corp.'s expansion into oncology. Although at the preclinical stage, this candidate represents the company's efforts to explore therapeutic options beyond CNS disorders, offering potential new avenues in cancer treatment.
- ANAVEX 1-41
Contact Information
